Literature DB >> 20638950

Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period.

Masanori Takaiwa1, Kunihiko Aya, Takayuki Miyai, Kosei Hasegawa, Motofumi Yokoyama, Youichi Kondo, Nobuyuki Kodani, Yoshiki Seino, Hiroyuki Tanaka, Tsuneo Morishima.   

Abstract

Fibroblast growth factor 23 (FGF23) is a potent regulator of Pi and 1,25-(OH)(2)D homeostasis. Early postpartum infants show intriguing changes in serum levels of Ca, Pi, PTH and 1,25-(OH)(2)D. However, the role of FGF23 in the early neonatal mineral metabolism has not been clarified. In order to evaluate the significance of FGF23 during the early postpartum period, we examined the circulating FGF23 levels using an intact FGF23 ELISA and a C-terminal FGF23 ELISA either in 22 umbilical cord blood samples (the cord blood) or in 22 term infants at 5days of life (the 5-day-old infant). We also compared these ranges with those of 11 healthy adults. Data were expressed as mean+/-SD, and analyzed by two-way ANOVA, followed by the Tukey's test. C-terminal FGF23 in the cord blood, the 5-day-old infants and the healthy adults were 73.3+/-22.4, 81.0+/-28.2 and 39.0+/-7.8 RU/ml, respectively. Intact FGF23 in the cord blood, the 5-day-old infants and the healthy adults were 3.9+/-1.6, 21.8+/-17.6, and 27.6+/-7.3 pg/ml, respectively. Immunoprecipitation assays using anti-FGF23 antibodies demonstrated that the intact 32 kDa FGF23 was low and the fragmented FGF23 of 18kDa was abundant in the cord blood compared with those in the healthy adults. In conclusion, our observations indicated that the intact FGF23/C-terminal FGF23 ratio was very low due to the fragmentation of FGF23 during the early postpartum period and might have a considerable contribution to the Pi homeostasis in the healthy term infants.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID: 20638950     DOI: 10.1016/j.bone.2010.05.024

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

Review 1.  Bone development in the fetus and neonate: role of the calciotropic hormones.

Authors:  Christopher S Kovacs
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

2.  FGF23 Is Not Required to Regulate Fetal Phosphorus Metabolism but Exerts Effects Within 12 Hours After Birth.

Authors:  Yue Ma; Beth J Kirby; Nicholas A Fairbridge; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

3.  Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization.

Authors:  Yue Ma; Manoharee Samaraweera; Sandra Cooke-Hubley; Beth J Kirby; Andrew C Karaplis; Beate Lanske; Christopher S Kovacs
Journal:  Endocrinology       Date:  2014-03-06       Impact factor: 4.736

Review 4.  Developmental changes in renal tubular transport-an overview.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2013-11-20       Impact factor: 3.714

5.  Cord Blood Ferritin and Fibroblast Growth Factor-23 Levels in Neonates.

Authors:  Farah N Ali; Jami Josefson; Armando J Mendez; Karen Mestan; Myles Wolf
Journal:  J Clin Endocrinol Metab       Date:  2016-02-09       Impact factor: 5.958

6.  Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease.

Authors:  Zhongyan Liu; Hao Zhou; Xiaoying Chen; Hong Chen; Yi Wang; Ting Wang; Luyan Cai; Yanyan Hong; Hailun Ke; Jing Zheng
Journal:  Int Urol Nephrol       Date:  2019-01-28       Impact factor: 2.370

7.  Serious neonatal morbidities are associated with differences in DNA methylation among very preterm infants.

Authors:  Todd M Everson; T Michael O'Shea; Amber Burt; Karen Hermetz; Brian S Carter; Jennifer Helderman; Julie A Hofheimer; Elisabeth C McGowan; Charles R Neal; Steven L Pastyrnak; Lynne M Smith; Antoine Soliman; Sheri A DellaGrotta; Lynne M Dansereau; James F Padbury; Barry M Lester; Carmen J Marsit
Journal:  Clin Epigenetics       Date:  2020-10-19       Impact factor: 7.259

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.